Terrey J P, Casey P A
Medical Department, SmithKline Beecham AG, Thörishaus, Switzerland.
Support Care Cancer. 1995 Nov;3(6):435-8. doi: 10.1007/BF00364988.
Data on the use of intravenous grainsetron (Kytril) were collected during a surveillance exercise amongst Swiss oncologists. The data were analysed to ascertain how grainsetron was used, and to document the incidence of adverse experiences in a clinical setting. Forty-nine oncologists at 40 Swiss centres were surveyed for their use of granisetron for the prevention and treatment of chemotherapy-induced nausea and vomiting. All were advised to follow the Swiss prescribing instructions for granisetron. They were invited to return data on patient demography, chemotherapy duration, granisetron dosing and adverse experiences. From 285 patients it was deduced that the mean daily dose of granisetron was 1.3 ampoules (3.9 mg) and the median daily dose was 1 ampoule (3 mg). The average number of doses of granisetron per patient per session was 3.8. There were 44 reports of adverse experiences by 34 patients, the most common report being headache. The survey confirmed that the large majority of patients undergoing chemotherapy required only a single dose of granisetron per day, and that the adverse experience profile was good.
在瑞士肿瘤学家开展的一项监测活动中收集了关于静脉使用格拉司琼（凯特瑞）的数据。对这些数据进行分析，以确定格拉司琼的使用方式，并记录临床环境中不良事件的发生率。对瑞士40个中心的49位肿瘤学家使用格拉司琼预防和治疗化疗引起的恶心和呕吐情况进行了调查。所有人员均被建议遵循瑞士格拉司琼的处方说明。邀请他们反馈有关患者人口统计学、化疗持续时间、格拉司琼剂量及不良事件的数据。从285名患者的数据推断，格拉司琼的日均剂量为1.3安瓿（3.9毫克），中位日剂量为1安瓿（3毫克）。每位患者每次化疗疗程使用格拉司琼的平均次数为3.8次。34名患者报告了44例不良事件，最常见的报告症状为头痛。该调查证实，绝大多数接受化疗的患者每天仅需一剂格拉司琼，且不良事件情况良好。
